8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934



        Date of Report (date of earliest event reported): March 26, 2004


                           Commission File No. 0-11178
                                               -------


                           UTAH MEDICAL PRODUCTS, INC.
             (Exact name of Registrant as specified in its charter)


                      UTAH                                    87-0342734
         -----------------------------------             ------------------
         (State or other jurisdiction of                   (I.R.S. Employer
         incorporation or organization)                 Identification No.)

                               7043 South 300 West
                               Midvale, Utah 84047
                     Address of principal executive offices


Registrant's telephone number:      (801) 566-1200
                                    --------------





- --------------------------------------------------------------------------------
                        ITEM 9. REGULATION FD DISCLOSURE
- --------------------------------------------------------------------------------


On March 26, 2004, Utah Medical Products, Inc. issued a press release, a copy of
which is attached hereto as Exhibit 99.1


- --------------------------------------------------------------------------------
                                   SIGNATURES
- --------------------------------------------------------------------------------

 Pursuant to the requirements of the Securities Exchanges Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                                UTAH MEDICAL PRODUCTS, INC.
                                                REGISTRANT


 Date:   3/29/2004                              By:      /s/ Kevin L. Cornwell
 -----------------------------------           --------------------------------
                                                             Kevin L. Cornwell
                                                             CEO





- --------------------------------------------------------------------------------
                                  EXHIBIT INDEX



Index
Number              Description

99.1                Press release issued March 26, 2004: Utah Medical Products,
                    Inc. Updates Status of FDA Inspection.

EX-99.1

                                  EXHIBIT 99.1

Salt Lake City, Utah - On February 11, Utah Medical Products, Inc. (NASDAQ:
UTMD) publicly disclosed a comprehensive inspection of its Utah facility by
three FDA inspectors from Minneapolis, Dallas and Denver which began on February
2. On March 4, UTMD reported conclusion of the inspection after five weeks and
issuance of FORM FDA-483 with inspectors' observations.

In response to shareholder questions regarding the results of the inspection,
UTMD announces that on March 16, it responded in detail to each of the seven
FDA-483 observations. The fifty-eight (58) page response letter appended five
exhibits of over six hundred (600) additional pages.

After a 2002 inspection, UTMD received a FDA-483 with thirteen (13)
observations. After a 2003 inspection by two inspectors, one of whom was a
questionable FDA "expert" in sterilization, UTMD received a FDA-483 with
nineteen (19) observations, including primary observations that included
statements that UTMD did not have any evidence of sterilization validation or
follow procedures for making proper MDR (injury) reports. If these observations
had been true, FDA could have had a basis to make accusations against UTMD. UTMD
has been firm in expressing its disagreement with the FDA and is particularly
pleased that neither of those issues was included in the 2004 FDA-483, because
the same quality system documentation that was reviewed in 2003 was reviewed in
2004.

UTMD believes its longstanding position has been vindicated on the basis that
the adequacy of UTMD's QSR procedures that have been in existence for years has
been verified. There were no current observations to suggest or support concern
about the safety or effectiveness of any devices manufactured and distributed by
UTMD. This last fact represents to UTMD the continuing confirmation of the
effectiveness of the UTMD Quality System that has been in place since prior to
the 2001 inspection and contradicts the position expressed by the FDA Denver
District Office in 2001.

The primary observation in the most recent 2004 FDA-483 alleges UTMD lacks
validation of its injection molding and extrusion operations. Yet, UTMD has
received supportive opinions from independent experts, one of whose active
involvement in the plastics industry includes training of FDA inspectors. Other
observations represented inspectors' opinions (not failure to follow explicit
FDA requirements), or were simply incorrect in part because of failure to place
the observation into proper context. When a handful of isolated and minor
documentation errors, which did not affect the quality of devices manufactured,
were identified these were promptly corrected. The rare documentation errors
were identified through review of thousands of pages, and represented isolated
human errors that did not affect the integrity of the UTMD Quality System.






As part of the March 16 written response, UTMD offered additional clarification
and further dialogue if needed to provide a fully exhaustive discussion of any
issues resulting from the inspection. UTMD and its consultants believe that the
FDA has sufficient evidence to support that UTMD has been and is in compliance
with a reasonable interpretation of the QSR and regards the FDA delay in
acknowledging this fact as further evidence of continued improper performance by
numerous FDA personnel. Given the scope of the improper behavior, UTMD believes
that its experience is not isolated within the industry. We again urge our
Congressional representatives who have a keen interest in the public health, a
desire to support innovation for an industry where regulators are often
responsible for its decline, and a sincere concern about jobs for law-abiding
citizens, to examine UTMD's experience as part of a formal investigation of
current FDA practices.

UTMD advises that its devices are of state of the art quality preferred in
particular by sophisticated clinician users, and that its devices conform to the
quality and performance represented by UTMD.

Utah Medical Products, Inc., with particular interest in health care for women
and their babies, develops, manufactures, assembles and markets a broad range of
disposable and reusable specialty medical devices designed for better health
outcomes for patients and their care-providers. For more information about Utah
Medical Products, Inc., visit UTMD's website at www.utahmed.com.
                                                ---------------